Atlas Trials

Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma

Clinical trial NCT05251662 · UNKNOWN

Trial details

NCT number
NCT05251662
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Intrahepatic Cholangiocarcinoma
Start date
2022-01-13
Primary completion
2024-01-13
Enrollment
90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.